Hong Kong-listed artificial intelligence drug-discovery company Insilico Medicine has struck a collaboration with US-headquartered Human Longevity to co-develop what they describe as “the industry’s first large-scale” AI foundation models capable of predicting diseases – such as cancer – decades before clinical symptoms appear. The partnership was announced as the global longevity market, fuelled by an ageing population and rising consumption demand, was valued at about US$5.3 trillion and…
Want more insights? Join Grow With Caliber - our career elevating newsletter and get our take on the future of work delivered weekly.
